Gymtrack co-founder Pablo Srugo joins Ottawa’s Mistral Venture Partners

After spending the better part of the past five years exercising his entrepreneurial muscles, Pablo Srugo has decided it's time to change up his business-building regimen. Srugo, who launched fitness technology startup Gymtrack with partner Lee Silverstone five years ago and helped grow the business to more than 35 employees, left the firm earlier this summer to join Ottawa-based venture capital fund Mistral Venture Partners as an associate.

Andreessen Horowitz reportedly plans new VC fund for black investors – CNET

Prominent Silicon Valley venture capital firm Andreessen Horowitz is launching a new venture capital fund that will target black celebrities, athletes and media personalities to boost diversity in tech, according to the Wall Street Journal . Initial limited partners in the fund include basketball star Kevin Durant, actor Will Smith and Essence magazine publisher Richelieu Dennis, the newspaper reported Monday, citing unidentified people familiar with the matter.

African tech leaders Fope Adelowo, Ken Njoroge, Tayo Oviosu to speak at Disrupt SF

Africa's startup scene is growing by leaps and bounds and three tech leaders are set to share insights on this vibrant space at Disrupt San Francisco. CEO Ken Njoroge will take the stage September 7 to discuss topics such as fintech, Africa's founder experience, data privacy, VC investment, and the continent's future unicorn and IPO prospects.

How This VC Aligns Her Networking With Her Fund’s Investment Thesis

Brenda Irwin is the founder and general partner of Relentless Venture Fund, a Vancouver, British Columbia, Canada based early-stage fund investing in preventative health and proactive technology solutions. Irwin's fund was one of the ten female founded venture capital funds I highlighted in my Forbes post " Ten Female Founded Venture Capital Funds You Should Have In Your Network ".

Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

Orchard Therapeutics , a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing. Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S. based healthcare focused funds.

US proptech fund Fifth Wall attracts Hong Kong, Asian interest

Fifth Wall Ventures, a California-based venture capital firm that manages dedicated property technology funds, is seeing a growing interest from Hong Kong and Asian property developers seeking to access new technologies. Its second fund, targeted at US$400 million, is anticipating investments from "a handful of" Hong Kong developers, according to market sources.